<DOC>
	<DOCNO>NCT01693315</DOCNO>
	<brief_summary>The objective dose-escalation study evaluate safety , tolerability efficacy AMA0076 reduction intraocular pressure subject ocular hypertension primary open-angle glaucoma .</brief_summary>
	<brief_title>Multiple Dose-escalation Study AMA0076 Patients With Ocular Hypertension Primary Open-angle Glaucoma</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Inclusion Criteria include : 1 . Adults 3085 year age 2 . Diagnosis either ocular hypertension primary openangle glaucoma eye 3 . Not receive medication IOP , able stop medication washout period duration study without significant risk adverse consequence relate glaucomatous disease 4 . Elevated IOP ( ≥ 24 ≤ 34 mm Hg 8 AM ≥ 21 ≤ 34 mm Hg 10 AM Screening Two visit Baseline visit one eye treatment Exclusion Criteria include : 1 . Uncontrolled intraocular hypertension define &gt; 34 mm Hg either screening/baseline visit ( washout phase subject currently receive ocular hypotensive therapy ) . 2 . Receiving one medication IOP time screen . 3 . Central corneal thickness le 500 µm great 620 µm . 4 . BCVA worse 20/200 either eye 5 . Significant visual field loss ( ie , mean deviation &gt; 10 db field loss within 10 degree fixation ) , new field defect , progression exist field defect either eye year precede study . 6 . Acute angleclosure glaucoma appositional narrow anterior chamber angle either eye .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>